

1. **Diagnosis** – type of dementia: \_\_\_\_\_  
*Do not routinely stop antipsychotic medication when prescribed for another indication like schizophrenia or mood disorders*
2. **Initial Target Systems** (Physical, Verbal, Psychotic (hallucinations/delusions), other)  
 - Describe all symptoms: \_\_\_\_\_
3. **Confirmation:** Assessment of target symptoms has been completed per BC BPSD Algorithm ([www.bcbpsd.ca](http://www.bcbpsd.ca)). Behaviour has not responded to comprehensive non-pharmacologic treatment plan, including removal of possibly offending drugs, and/or behaviour is dangerous, distressing, disturbing, damaging to social relationships and persistent.

**Examples of BPSD Usually Not Amenable to Antipsychotic Treatment**

- Wandering
- Hiding and hoarding
- Repetitive activity
- Vocally disruptive behaviour
- Inappropriate (un)dressing
- Tugging at seatbelts
- Inappropriate voiding
- Eating inedible objects
- Pushing wheelchair-bound co-residents

*Note: avoid use of antipsychotics if possible for clients with dementia due to Parkinson’s or Lewy Body. Cholinesterase Inhibitors are first line treatment for clients with psychosis associated with these dementias.*

**Part 1: Initiate (Regular and/or PRN) – For Responsive Symptoms**

4. Choose the regular dose, and PRN if necessary including indication, interval and maximum daily dose
5. Monitoring: Review effectiveness and S/E’s in one week
6. Consent for treatment – Emergency ‘OR’ risk/benefits discussion with resident (if capable) or Substitute Decision Maker (SDM) (if incapable) - consent should be ahead of monitoring

*Risks to be discussed with patient (if capable) and/or SDM should include, but not limited to, the following side effects:*

- Oversedation
- Risk of falls
- Confusion
- Tardive dyskinesia
- Extra pyramidal symptoms
- Metabolic syndrome
- Stroke
- Prolonged QTc
- Increased mortality
- Postural hypotension

**Examples of Commonly Used Antipsychotic Dosages for Elderly\***

*\*This information is intended as a guide only. For full prescribing information, please see product monograph for each drug.*

Medication	Starting Dose (mg)	Dosing Frequency	Incremental Dose (mg)	Average Total Daily Dose
Risperidone	0.25	Daily / BID	0.25 Q3 – 7 days	1 mg
Olanzapine	1.25 to 2.5	HS / BID	1.25 to 2.5 Q3 – 7 days	5 mg
Aripiprazole	2	Daily	2 to 5 Q Weekly	10 mg
Quetiapine	12.5 to 25	BID/ TID / HS (if XR)	12.5 to 25 Q3 – 7 days	150 mg
Loxapine	2.5	BID	2.5 to 5 Q3 – 7 days	20 mg
Haloperidol	0.25 to 0.5	Daily / BID	0.25 to 0.5 Q3 – 7 days	2 mg

**Part 2: Titration/ Review**

7. **Indications for review:**
  - New Admission
  - Current antipsychotic and dose requires review
  - Or, other
  - Drug related problem
  - Initial target symptoms haven’t improved in frequency and/or intensity
8. **Medication/Dose Options** (see incremental doses in chart above)
  - Titrate dose
  - Titrate PRN
  - Start new medication and /or PRN if current is ineffective after therapeutic trial or person unable to tolerate
  - Continue same dose &/or PRN
  - Discontinue (see Part 3)

9. **Monitoring:**  
 Reassess effectiveness and S/E’s q2 to 4 weeks.

**Part 3: Dose Reduction Trial**

*If target symptoms are stable at 3 to 6 months, then consider tapering dose ‘OR’ Dose Reduction Trial*  
 Rapid or abrupt decrease may cause withdrawal dyskinesia.  
 Gradual dose reduction is safe and may improve function.

- Aripiprazole – reduce daily dose by 1mg
- Loxapine – reduce daily dose by 2.5mg
- Olanzapine – reduce daily dose by 1.25 to 2.5mg
- Quetiapine – reduce daily dose by 12.5 to 25mg
- Risperidone – reduce daily dose by 0.25mg
  - a. Observe daily for target symptom recurrence
  - b. Review every 2-4 weeks for further dose reduction if target symptoms are reduced or manageable.

<sup>1</sup> The information in this practice sheet is adapted with permission from: *IH BPSD Antipsychotic Preprinted Order Series (2014)*, created by the Interior Health Antipsychotic/BPSD Working Group, and approved for clinical practice within Interior Health. Grateful acknowledgement is made to Dr. Carol Ward for her expertise in guiding the development of these PPOs.

<sup>2</sup> This information sheet is a resource of the BC BPSD Algorithm (2014) ([www.bcbpsd.ca](http://www.bcbpsd.ca)), a clinical practice decision support tool within the [BC Best Practice Guidelines for Managing and Accommodating BPSD in Residential Care](#) (2012), and is best used within this context.

<sup>3</sup> *Disclaimer:* Information is intended for general clinical direction only, and doesn’t replace individual professional judgment. No liability